Chemicals
Build Your Comparison
Side-by-side financial analysisStock Comparison
ORGN vs VVOS vs JPM vs BAC vs ALGN
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Banks - Diversified
Banks - Diversified
Medical - Devices
ORGN vs VVOS vs JPM vs BAC vs ALGN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Chemicals | Medical - Devices | Banks - Diversified | Banks - Diversified | Medical - Devices |
| Market Cap | $6M | $3M | $908.57B | $424.14B | $13.04B |
| Revenue (TTM) | $14M | $20M | $280.33B | $191.57B | $4.10B |
| Net Income (TTM) | $-241M | $-25M | $57.05B | $30.51B | $430M |
| Gross Margin | -4.4% | 59.5% | 60.0% | 56.1% | 67.7% |
| Operating Margin | -459.3% | -115.5% | 25.9% | 19.7% | 14.4% |
| Forward P/E | — | — | 14.6x | 12.6x | 16.0x |
| Total Debt | $28M | $14M | $942.38B | $365.90B | $114M |
| Cash & Equiv. | $33M | $2M | $343.34B | $231.84B | $1.08B |
ORGN vs VVOS vs JPM vs BAC vs ALGN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 20 | Jun 26 | Return |
|---|---|---|---|
| Origin Materials, I… (ORGN) | 100 | 0.3 | -99.7% |
| Vivos Therapeutics,… (VVOS) | 100 | 0.3 | -99.7% |
| JPMorgan Chase & Co. (JPM) | 100 | 255.9 | +155.9% |
| Bank of America Cor… (BAC) | 100 | 185.4 | +85.4% |
| Align Technology, I… (ALGN) | 100 | 34.1 | -65.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ORGN vs VVOS vs JPM vs BAC vs ALGN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ORGN is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.54, Low D/E 26.6%, current ratio 2.83x
VVOS has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 16.0%, EPS growth 7.2%, 3Y rev CAGR 2.9%
- 16.0% revenue growth vs ORGN's -39.5%
- Beta 0.51 vs ALGN's 1.61
JPM is the #2 pick in this set and the best alternative if long-term compounding and bank quality is your priority.
- 481.2% 10Y total return vs BAC's 371.6%
- NIM 2.2% vs BAC's 1.8%
- 20.4% margin vs ORGN's -17.2%
- 1.8% yield, 15-year raise streak, vs BAC's 2.3%, (3 stocks pay no dividend)
BAC ranks third and is worth considering specifically for income & stability and valuation efficiency.
- Dividend streak 12 yrs, beta 0.83, yield 2.3%
- PEG 0.82 vs JPM's 0.83
- Beta 0.83, yield 2.3%, current ratio 0.42x
- Lower P/E (12.6x vs 16.0x)
ALGN is the clearest fit if your priority is efficiency.
- 6.9% ROA vs ORGN's -99.5%, ROIC 15.4% vs -24.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.0% revenue growth vs ORGN's -39.5% | |
| Value | Lower P/E (12.6x vs 16.0x) | |
| Quality / Margins | 20.4% margin vs ORGN's -17.2% | |
| Stability / Safety | Beta 0.51 vs ALGN's 1.61 | |
| Dividends | 1.8% yield, 15-year raise streak, vs BAC's 2.3%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +27.2% vs ORGN's -91.8% | |
| Efficiency (ROA) | 6.9% ROA vs ORGN's -99.5%, ROIC 15.4% vs -24.4% |
ORGN vs VVOS vs JPM vs BAC vs ALGN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ORGN vs VVOS vs JPM vs BAC vs ALGN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 2 of 6 categories
ALGN leads 1 • ORGN leads 0 • VVOS leads 0 • BAC leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 20068.2x ORGN's $14M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to ORGN's -17.2%. On growth, VVOS holds the edge at +70.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $14M | $20M | $280.3B | $191.6B | $4.1B |
| EBITDAEarnings before interest/tax | -$55M | -$21M | $81.4B | $40.0B | $790M |
| Net IncomeAfter-tax profit | -$241M | -$25M | $57.0B | $30.5B | $430M |
| Free Cash FlowCash after capex | -$59M | -$18M | $100.9B | $12.6B | $717M |
| Gross MarginGross profit ÷ Revenue | -4.4% | +59.5% | +60.0% | +56.1% | +67.7% |
| Operating MarginEBIT ÷ Revenue | -4.6% | -115.5% | +25.9% | +19.7% | +14.4% |
| Net MarginNet income ÷ Revenue | -17.2% | -128.4% | +20.4% | +15.9% | +10.5% |
| FCF MarginFCF ÷ Revenue | -4.3% | -93.3% | +36.0% | +6.6% | +17.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -91.2% | +70.5% | — | — | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +39.3% | -15.6% | +16.0% | +18.3% | +23.6% |
Valuation Metrics
Evenly matched — VVOS and JPM and BAC each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 14.7x trailing earnings, BAC trades at a 54% valuation discount to ALGN's 32.2x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 0.92x vs BAC's 0.96x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $6M | $3M | $908.6B | $424.1B | $13.0B |
| Enterprise ValueMkt cap + debt − cash | $781,018 | $14M | $1.51T | $558.2B | $12.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.02x | -0.24x | 16.22x | 14.71x | 32.23x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 14.60x | 12.60x | 16.01x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.92x | 0.96x | — |
| EV / EBITDAEnterprise value multiple | — | — | 18.52x | 13.95x | 15.15x |
| Price / SalesMarket cap ÷ Revenue | 0.32x | 0.17x | 3.25x | 2.21x | 3.23x |
| Price / BookPrice ÷ Book value/share | 0.05x | — | 2.51x | 1.40x | 3.26x |
| Price / FCFMarket cap ÷ FCF | — | — | 9.01x | 33.63x | 26.57x |
Profitability & Efficiency
ALGN leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-23 for VVOS. ALGN carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), BAC scores 7/9 vs VVOS's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -120.7% | -23.4% | +15.9% | +10.1% | +10.7% |
| ROA (TTM)Return on assets | -99.5% | -98.6% | +1.3% | +0.9% | +6.9% |
| ROICReturn on invested capital | -24.4% | -2.3% | +4.5% | +3.5% | +15.4% |
| ROCEReturn on capital employed | -25.7% | -2.3% | +8.9% | +4.5% | +14.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 | 5 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.27x | — | 2.60x | 1.21x | 0.03x |
| Net DebtTotal debt minus cash | -$5M | $11M | $599.0B | $134.1B | -$965M |
| Cash & Equiv.Liquid assets | $33M | $2M | $343.3B | $231.8B | $1.1B |
| Total DebtShort + long-term debt | $28M | $14M | $942.4B | $365.9B | $114M |
| Interest CoverageEBIT ÷ Interest expense | -2627.81x | — | 0.74x | 0.48x | 389.13x |
Total Returns (Dividends Reinvested)
JPM leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $23,548 today (with dividends reinvested), compared to $37 for ORGN. Over the past 12 months, BAC leads with a +27.2% total return vs ORGN's -91.8%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.7% vs ORGN's -79.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -84.6% | -80.2% | +0.8% | +1.4% | +16.7% |
| 1-Year ReturnPast 12 months | -91.8% | -79.8% | +20.9% | +27.2% | +1.1% |
| 3-Year ReturnCumulative with dividends | -99.1% | -96.1% | +138.8% | +105.5% | -45.1% |
| 5-Year ReturnCumulative with dividends | -99.6% | -99.6% | +135.5% | +57.4% | -69.7% |
| 10-Year ReturnCumulative with dividends | -99.6% | -99.8% | +481.2% | +371.6% | +128.5% |
| CAGR (3Y)Annualised 3-year return | -79.4% | -66.0% | +33.7% | +27.1% | -18.1% |
Risk & Volatility
Evenly matched — VVOS and BAC each lead in 1 of 2 comparable metrics.
Risk & Volatility
VVOS is the less volatile stock with a 0.51 beta — it tends to amplify market swings less than ALGN's 1.61 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BAC currently trades 96.9% from its 52-week high vs ORGN's 3.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.54x | 0.51x | 0.87x | 0.83x | 1.61x |
| 52-Week HighHighest price in past year | $28.49 | $7.95 | $338.09 | $57.98 | $208.31 |
| 52-Week LowLowest price in past year | $0.20 | $0.45 | $269.72 | $44.21 | $122.00 |
| % of 52W HighCurrent price vs 52-week peak | +3.8% | +6.3% | +96.2% | +96.9% | +87.4% |
| RSI (14)Momentum oscillator 0–100 | 33.6 | 34.2 | 72.1 | 70.9 | 51.9 |
| Avg Volume (50D)Average daily shares traded | 563K | 299K | 7.4M | 32.4M | 915K |
Analyst Outlook
Evenly matched — JPM and BAC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ORGN as "Buy", JPM as "Buy", BAC as "Buy", ALGN as "Buy". Consensus price targets imply 8156.9% upside for ORGN (target: $90) vs 4.5% for JPM (target: $340). For income investors, BAC offers the higher dividend yield at 2.25% vs JPM's 1.83%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $90.00 | — | $339.75 | $61.13 | $203.60 |
| # AnalystsCovering analysts | 6 | — | 61 | 54 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.8% | +2.3% | — |
| Dividend StreakConsecutive years of raises | 1 | — | 15 | 12 | — |
| Dividend / ShareAnnual DPS | — | — | $5.95 | $1.27 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.8% | +5.1% | +3.6% |
JPM leads in 2 of 6 categories (Income & Cash Flow, Total Returns). ALGN leads in 1 (Profitability & Efficiency). 3 tied.
ORGN vs VVOS vs JPM vs BAC vs ALGN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ORGN or VVOS or JPM or BAC or ALGN a better buy right now?
For growth investors, Vivos Therapeutics, Inc.
(VVOS) is the stronger pick with 16. 0% revenue growth year-over-year, versus -39. 5% for Origin Materials, Inc. (ORGN). Bank of America Corporation (BAC) offers the better valuation at 14. 7x trailing P/E (12. 6x forward), making it the more compelling value choice. Analysts rate Origin Materials, Inc. (ORGN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ORGN or VVOS or JPM or BAC or ALGN?
On trailing P/E, Bank of America Corporation (BAC) is the cheapest at 14.
7x versus Align Technology, Inc. at 32. 2x. On forward P/E, Bank of America Corporation is actually cheaper at 12. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Bank of America Corporation wins at 0. 82x versus JPMorgan Chase & Co. 's 0. 83x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ORGN or VVOS or JPM or BAC or ALGN?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +135. 5%, compared to -99. 6% for Origin Materials, Inc. (ORGN). Over 10 years, the gap is even starker: JPM returned +481. 2% versus VVOS's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ORGN or VVOS or JPM or BAC or ALGN?
By beta (market sensitivity over 5 years), Vivos Therapeutics, Inc.
(VVOS) is the lower-risk stock at 0. 51β versus Align Technology, Inc. 's 1. 61β — meaning ALGN is approximately 217% more volatile than VVOS relative to the S&P 500. On balance sheet safety, Align Technology, Inc. (ALGN) carries a lower debt/equity ratio of 3% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — ORGN or VVOS or JPM or BAC or ALGN?
By revenue growth (latest reported year), Vivos Therapeutics, Inc.
(VVOS) is pulling ahead at 16. 0% versus -39. 5% for Origin Materials, Inc. (ORGN). On earnings-per-share growth, the picture is similar: Bank of America Corporation grew EPS 18. 6% year-over-year, compared to -188. 2% for Origin Materials, Inc.. Over a 3-year CAGR, VVOS leads at 2. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ORGN or VVOS or JPM or BAC or ALGN?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -1319. 6% for Origin Materials, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -335. 4% for ORGN. At the gross margin level — before operating expenses — ALGN leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ORGN or VVOS or JPM or BAC or ALGN more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Bank of America Corporation (BAC) is the more undervalued stock at a PEG of 0. 82x versus JPMorgan Chase & Co. 's 0. 83x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bank of America Corporation (BAC) trades at 12. 6x forward P/E versus 16. 0x for Align Technology, Inc. — 3. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ORGN: 8156. 9% to $90. 00.
08Which pays a better dividend — ORGN or VVOS or JPM or BAC or ALGN?
In this comparison, BAC (2.
3% yield), JPM (1. 8% yield) pay a dividend. ORGN, VVOS, ALGN do not pay a meaningful dividend and should not be held primarily for income.
09Is ORGN or VVOS or JPM or BAC or ALGN better for a retirement portfolio?
For long-horizon retirement investors, JPMorgan Chase & Co.
(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Origin Materials, Inc. (ORGN) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +481. 2%, ORGN: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ORGN and VVOS and JPM and BAC and ALGN?
These companies operate in different sectors (ORGN (Basic Materials) and VVOS (Healthcare) and JPM (Financial Services) and BAC (Financial Services) and ALGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ORGN is a small-cap quality compounder stock; VVOS is a small-cap high-growth stock; JPM is a large-cap deep-value stock; BAC is a large-cap deep-value stock; ALGN is a mid-cap quality compounder stock. JPM, BAC pay a dividend while ORGN, VVOS, ALGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.